TransMedics Group (TMDX) is down 4.8% today. Here is some analysis on what might have caused this price movement.
Analysis: The sell-off appears tied mainly to the company’s newly announced chief financial officer transition, even though management reaffirmed full-year 2026 revenue guidance. Leadership changes in a high-growth medtech name can unsettle investors, especially when there was no new upside revision alongside the announcement.
Details:
Sources:
TransMedics, SEC
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$TMDX Insider Trading Activity
$TMDX insiders have traded $TMDX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TMDX stock by insiders over the last 6 months:
- THOMAS J. GUNDERSON sold 9,624 shares for an estimated $722,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TMDX Hedge Fund Activity
We have seen 198 institutional investors add shares of $TMDX stock to their portfolio, and 281 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. removed 642,995 shares (-61.9%) from their portfolio in Q2 2026, for an estimated $42,707,727
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 541,273 shares (-57.6%) from their portfolio in Q2 2026, for an estimated $35,951,352
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 328,666 shares (+inf%) to their portfolio in Q2 2026, for an estimated $21,829,995
- TWO SIGMA INVESTMENTS, LP removed 316,195 shares (-97.2%) from their portfolio in Q2 2026, for an estimated $21,001,671
- GOLDMAN SACHS GROUP INC removed 306,511 shares (-35.4%) from their portfolio in Q2 2026, for an estimated $20,358,460
- BLACKROCK, INC. added 303,218 shares (+5.7%) to their portfolio in Q2 2026, for an estimated $20,139,739
- PRICE T ROWE ASSOCIATES INC /MD/ removed 300,655 shares (-86.7%) from their portfolio in Q2 2026, for an estimated $19,969,505
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TMDX Price Targets
Multiple analysts have issued price targets for $TMDX recently. We have seen 7 analysts offer price targets for $TMDX in the last 6 months, with a median target of $120.0.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $90.0 on 07/06/2026
- Joshua Jennings from TD Cowen set a target price of $120.0 on 07/01/2026
- William Plovanic from Canaccord Genuity set a target price of $124.0 on 06/30/2026
- Tom Stephan from Stifel set a target price of $80.0 on 06/18/2026
- Mike Matson from Needham set a target price of $142.0 on 05/06/2026
- Matt O'Brien from Piper Sandler set a target price of $120.0 on 05/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
